FIG 4.

Effects of proteasomal and lysosomal inhibitors on ORF7a antagonism of BST-2. (A and B) HEK293T cells were treated with either ConA or MG-132 to demonstrate that the concentrations used are inhibitory to proteasomal or lysosomal degradation, respectively. The lysate was analyzed by Western blotting with antibodies against ubiquitin (α-Ub) (A) and LC3B (B) to demonstrate the efficacies of the compounds. (C) Increasing amounts of ORF7a were transfected into HEK293T cells. The cells were subsequently treated with the lysosome inhibitor concanamycin A or the proteasome inhibitor MG-132. Neither inhibitor prevented BST-2 antagonism by ORF7a. The data shown are representative of those from three independent experiments. The numbers next to the gels in panels A to C are molecular masses (in kilodaltons).